HPN-328 is a monoclonal antibody commercialized by Harpoon Therapeutics, with a leading Phase II program in Small-Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of HPN-328’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for HPN-328 is expected to reach an annual total of $94 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
HPN-328 is under development for the treatment of small-cell lung cancer, neuroendocrine prostate cancer and other neuroendocrine neoplasm like colorectal cancer, pancreatic cancer, thymic carcinoma, bladder cancer. The drug candidate is a single polypeptide comprising a single-chain variable fragment (scFv) targeting cancer surface antigen DLL3 and two single-domain antibodies that binds to the CD3 epsilon subunit of the TCR and to human serum albumin. It is a tri-specific antibody and T cell engager. It is developed based on tri-specific T-cell activating construct (TriTAC) technology. It is administered through intravenous route.
Harpoon Therapeutics Overview
Harpoon Therapeutics (Harpoon) is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company’s pipeline products include Hpn424, a T cell-engaging bispecific antibody used for the treatment of prostate cancer; HPN536 against ovarian cancer; HPN217 targeting Multiple Myeloma; HPN328 indicated for small cell lung cancer; and HPN601, is a protease-activated EpCAM targeting T cell engager for the treatment of solid tumors. It utilizes Tri-specific T cell activating construct (TriTAC) platform, for developing a pipeline of novel T cell engagers designed for targeted penetration and destruction of solid tumors and hematologic malignancies. Harpoon is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$31.9 million for the fiscal year ended December 2022 (FY2022), an increase of 34.9% over FY2021. The operating loss of the company was US$68.3 million in FY2022, compared to an operating loss of US$116.8 million in FY2021. The net loss of the company was US$67.7 million in FY2022, compared to a net loss of US$116.7 million in FY2021.
For a complete picture of HPN-328’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.